Thus, for early-stage HER2-positive breast cancer, neoadjuvant treatment with T-DM1, lapatinib, and nab-paclitaxel is more effective than standard treatment, especially in the ER-positive patient population (Patel et al., 2019). Here, ERBB2 is linked to breast cancer.